Tradestie Institutional Equity Comparison Engine
ERAS vs DSGN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ERAS Overall Edge
ERAS Captures Institutional Edge (2โ1 Pillars ยท 2โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Erasca, Inc. Common Stock (ERAS) driven by superior Momentum & Technical, Options & Structure while DSGN counters with relative strength in Growth & Margin. Fundamentally, ERAS trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DSGN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ERAS sits in BREAKDOWN (13th %ile IV; Dealer Gamma Walls on Pro) against DSGN sits in BREAKDOWN (13th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ERAS N/M vs DSGN N/M Fwd P/E
Growth & Margin Winner
DSGN
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
ERAS
1Y +488.4% vs +40.8% ยท 52W Pos 57% vs 30%
Options & Structure Winner
ERAS
BREAKDOWN (13th %ile IV) vs BREAKDOWN (13th %ile IV)
ERAS
NASDAQ
Erasca, Inc. Common Stock
Pharmaceutical Preparations
$14.95
-4.57% 1D
Market Cap
$5.5B
1M Return
+11.61%
1Y Return
+488.39%
Forward P/E
N/M
Unified AI Score
37.5 / 100
SELL
Tech 20.0
Fund 47.0
Flow 70.0
Mom 64.0
DSGN
NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap
$677.5M
1M Return
-3.59%
1Y Return
+40.79%
Forward P/E
N/M
Unified AI Score
49.8 / 100
HOLD
Tech 55.0
Fund 57.0
Flow 63.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ERAS +488.39%
DSGN +40.79%
Spread: +447.6 pp (ERAS Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ERAS TTM Op. Margin: 0.0%
DSGN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ERAS vs DSGN. Trailing 12-month operating profitability (ERAS 0.0% vs DSGN 0.0%) and valuation multiples (ERAS N/M vs DSGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ERAS | DSGN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $5.5B | $677.5M | Larger Scale | ERAS |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -48.7% | -36.9% | Higher ROE | DSGN |
| 52-Week Range Position Momentum | 57% ($2โ$24) | 30% ($7โ$17) | Stronger Trend | ERAS |
| Beta / 30D Volatility Risk Regime | 2.31ฮฒ ยท 81% Vol | 1.32ฮฒ ยท 61% Vol | Lower Realized Risk | DSGN |
| Unified Institutional Score Composite Signal | 37.5 / 100 (SELL) | 49.8 / 100 (HOLD) | Higher Composite | DSGN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ERAS vs DSGN Buy Guide
ERAS
BREAKDOWN
87d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
DSGN
BREAKDOWN
139d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ERAS nor DSGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.